Lake Street analyst Brooks O’Neil downgraded Surmodics to Hold from Buy with a price target of $43, down from $75, after the company agreed to be acquired by GTCR for $43.00 per share in cash. The firm does not believe there will be another bid and expects the transaction to close, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRDX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue